AusperBio Completes $120 Million Series C Financing to Advance AHB-137 Toward Potential Commercialization and Expand Next-Generation HBV Therapies

AHB-137AHB-171Positive

AI Analysis

Summary

AusperBio completed a $120 million Series C financing round to advance AHB-137 through Phase 3 registrational program and commercialization, while accelerating development of next-generation HBV therapies including AHB-171.

Clinical Trial Data

Phase

Phase 3

Importance:7/10

Sentiment:

0.70

Series C financinghepatitis BPhase 3commercializationfunctional cure

Related Companies

$GBIO $MEHA

Read the original article

Published by PR Newswire Biotech on August 28, 2026 12:00 AM

Read Original